CagriSema

Overview

CagriSema is a once-weekly fixed-dose combination of two molecules from Novo Nordisk: semaglutide, the GLP-1 receptor agonist already familiar from Ozempic and Wegovy, and cagrilintide, a long-acting analog of the hormone amylin. The idea is to attack appetite and energy intake through two complementary pathways at once — GLP-1 and amylin — rather than maximizing a single mechanism. It is a late-stage pharmaceutical developed for obesity and type 2 diabetes, not a research peptide, and it is delivered as a single combined injection rather than two separate shots.

The combination sits alongside tirzepatide (GLP-1 + GIP) and retatrutide (GLP-1 + GIP + glucagon) in the wave of "combination" obesity drugs, but CagriSema is distinctive in pairing GLP-1 with amylin specifically. For the full evidence picture, see the CagriSema deep dive and our GLP-1 complete guide.

How it works

Semaglutide mimics GLP-1, slowing gastric emptying, increasing satiety, and improving glucose-dependent insulin secretion. Cagrilintide mimics amylin, a hormone co-secreted with insulin from the pancreas that acts largely in the brainstem to promote fullness and further slow gastric emptying. Because amylin and GLP-1 engage distinct receptors and partly distinct circuits, the combination is designed to produce additive appetite suppression — and potentially to blunt some of the weight-regain and plateau dynamics that limit single-mechanism therapy. Cagrilintide is engineered for a long half-life so it can be co-dosed once weekly with semaglutide.

What the evidence actually shows

In REDEFINE 1, the pivotal phase 3 obesity trial in adults without diabetes, CagriSema produced roughly 20-22% average weight loss over 68 weeks — a top-tier result broadly in tirzepatide's band and well above semaglutide alone. A phase 2 trial in type 2 diabetes also showed improved glucose control and weight with the combination. The widely-reported "disappointment" around CagriSema was a market reaction to analyst expectations that had been priced higher than ~20%, not a clinical failure: a ~20% average weight loss remains excellent by any historical standard.

There is no head-to-head trial yet against tirzepatide or retatrutide, so cross-trial comparisons should be read cautiously — differences in population, duration, and titration can account for small gaps. The honest read is that CagriSema is a strong, mechanistically distinct entry in the combination era rather than a clear winner or loser.

Safety and side effects

CagriSema carries the familiar GLP-1 side-effect profile, dominated by gastrointestinal effects — nausea, vomiting, diarrhea, and constipation — most pronounced during dose titration and the main reason it is escalated slowly. The class-level cautions apply: a boxed-warning consideration regarding thyroid C-cell tumors (contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2), and signals for pancreatitis and gallbladder disease. As with the rest of the class, large weight loss includes some lean mass, which protein intake and resistance training help preserve, and the reproductive rules apply — a planned pre-conception stop with washout.

CagriSema is a prescribed, monitored medicine. It is not something to source through the gray-market channels research peptides travel, and dosing belongs with a clinician. For management of the GI effects, see our GLP-1 side-effects guide.

The bottom line

CagriSema pairs semaglutide with the amylin analog cagrilintide to suppress appetite through two pathways, delivering roughly 20-22% average weight loss in REDEFINE 1 — a top-tier figure even though it undershot inflated expectations. With no head-to-head data yet against tirzepatide or retatrutide, it's best understood as a strong, distinct option in an obesity-drug field that is maturing into a menu of mechanistically different combinations.